Osteoporosis in systemic lupus erythematosus: Prevention and treatment

Lupus

Volumn 10, Issue 3, 2001, Pages 227-232

  Sen, D ^a   Keen, R W ^a  

^a ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonates; Calcium; Fracture; Osteoporosis; Vitamin D

Indexed keywords

CALCITONIN; CALCIUM; CORTICOSTEROID; METHOTREXATE; PHOSPHONIC ACID DERIVATIVE; THIAZIDE DIURETIC AGENT; VITAMIN D; WARFARIN;

BONE ATROPHY; BONE MINERAL; COMORBIDITY; FRACTURE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; LIFESTYLE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN SUPPLEMENTATION;

CALCIUM; DIPHOSPHONATES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OSTEOPOROSIS; VITAMIN D;

EID: 0035049898     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301671413439     Document Type: Review

References (58)

1. Consensus development conference: Prophylaxis and treatment of osteoporosis
2. Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: A preliminary study with dual energy X-ray absorptiometry
3. Metacarpal bone mass in systemic lupus erythematosus
4. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus
5. Loss of trabecular bone mineral density in systemic lupus erythematosus
6. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids
7. SLE and osteoporosis: Dependence and/or independence on glucocorticoids
8. The effect of systemic lupus erythematosus and long term steroid therapy on bone mass in premenopausal women
9. Bone metabolism and bone mineral density of systemic lupus erytematosus at the time of diagnosis
10. Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus
11. Systemic lupus erythematosus: Clinical features in patients with a disease duration of over 10y, first evaluation
12. Bone density at various sites for prediction of hip fractures
13. Frequency of fractures in women with systemic lupus erythematosus
14. Risk factors for hip fracture in white women
15. The 1982 revised criteria for the classification of systemic lupus erythematosus
16. Determinants of bone mass in systemic lupus erythematosus: A cross sectional study on pre-menopausal women
17. Bone mineral density in systemic lupus erythematosus: Comparison with rheumatoid arthritis and healthy controls
18. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: Deleterious role of glucocorticoid therapy at the lumbar spine
19. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus
20. Analysis of gene expression in human bone biopsies by polymerase chain reaction: Evidence for enhanced cytokine expression in postmenopausal osteoporosis
21. Postmenopausal osteoporosis: How the hormonal changes of menopause cause bone loss
22. Generalised bone loss in patients with early rheumatoid arthritis
23. Rheumatoid arthritis, corticosterold therapy and the risk of hip fracture
24. Osteoporosis in patients with rheumatic diseases
25. Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus
26. Use of oral corticosteroids and risk of fractures
27. Steroid osteoporosis
28. Bone loss in response to long-term glucocorticoid therapy
29. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis
30. Mechanism of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis
31. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells
32. Plasma testosterone concentration in asthmatic men treated with glucocorticoids
33. Hormonal status in normal, osteoporotic and corticostemid-treated postmenopausal women
34. Damage in systemic lupus erythematosus and its association with corticosteroids
35. Osteoporosis in patients with rheumatic diseases
36. Impaired carboxylation of osteocalcin in warfarin treated patients
37. Warfarin and fracture risk
38. Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells
39. A UK consensus group on management of glucocorticoid-induced osteoporosis: An update
40. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis
41. Corticosteroid osteoporosis: Practical implications of recent trials
42. The role of vitamin D in corticosteroid-induced osteoporosis
43. Effect of calcitriol on bone mineral density in premenopausal women taking chronic steroid therapy. A randomised, double blind controlled study
44. Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: A randomised cotrolled trial of calcitriol and hormone replacement therapy
45. The safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE)
46. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
47. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
48. Dehydroepiandrosterone in systemic lupus erythematosus
49. Prevention of corticosteroid osteoporosis- a comparison of calcium, calcitriol and calcitonin
50. Prevention of corticosteroid induced osteoporosis with salmon calcitonin in sarcoid patients
51. A randomised controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica
52. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: A two year follow up study
53. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
54. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
55. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
56. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European corticosteroid-induced osteoporosis treatment study
57. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis